BioMS says its lead drug has received a fast-track designation from the FDA

EDMONTON - Drug developer BioMS Medical Corp. said Thursday the U.S. Food and Drug Administration had granted its lead multiple sclerosis compound "fast track" status, which may expedite the drug's review process....More